Abstract: A method includes determining, for one or more variables that describe a potential subject for a study, corresponding functions representing a relationship between the one or more variables and (i) an estimated burden or (ii) an estimated burden reduction that would be imposed on the potential subject by a protocol of the study if the potential subject were to participate in the study. The estimated burden or the estimated burden reduction is dependent on subject-specific values for the one or more variables absent participation of the potential subject in the study. The method includes using the corresponding functions to determine, for each individual of a plurality of individuals, a set of estimated burden values or estimated burden reduction values associated with the one or more variables. The method also includes identifying a subset of the plurality of individuals or a patient profile to be prioritized for recruitment for the study.

Abstract: The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The disclosure also relates to method of using the compound of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, for treating diseases such as cancer, including colorectal cancer.

Abstract: The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The disclosure also relates to method of using the compound of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, for treating diseases such as cancer, including colorectal cancer.

Abstract: Provided herein are compounds identified as inhibitors of KRAS protein activity that can be used to treat various diseases and disorders, such as cancer.

Abstract: The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitor enantiomers of formula (I), (Ia), (Ib), (II), (IIa), or (IIb), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, with high enantiomeric excess (% ee). The disclosure also relates to method of using the compound of formula (I), (Ia), (Ib), (II), (IIa), or (IIb), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, for treating diseases such as cancer, including colorectal cancer.

Abstract: The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The disclosure also relates to method of using the compound of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, for treating diseases such as cancer, including colorectal cancer.

Abstract: Embodiments of the present disclosure include a system, method, and apparatus comprising a direct steam generator configured to generate saturated steam or superheated steam and combustion exhaust constituents. A CONVAPORATOR™ Unit (CU) can be fluidly coupled to the direct steam generator. The CU can be configured to route the saturated steam or superheated steam and combustion exhaust constituents through a condenser portion of the CU via a condenser side steam conduit and can be configured to condense the super-heated steam or saturated steam to form a condensate. A separation tank and water return system can be fluidly coupled to a condenser side condensate conduit of the condenser portion of the CU. The separation tank and water return system can be configured to separate the combustion exhaust constituents from the condensate. An evaporator portion of the CU can be fluidly coupled with the separation tank and water return system via an evaporator side condensate conduit.

Abstract: The present disclosure concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and R3 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cancer.

Abstract: Embodiments of the present disclosure include a system, method, and apparatus comprising a direct steam generator configured to generate saturated steam or superheated steam and combustion exhaust constituents. A CONVAPORATOR™ Unit (CU) can be fluidly coupled to the direct steam generator. The CU can be configured to route the saturated steam or superheated steam and combustion exhaust constituents through a condenser portion of the CU via a condenser side steam conduit and can be configured to condense the super-heated steam or saturated steam to form a condensate. A separation tank and water return system can be fluidly coupled to a condenser side condensate conduit of the condenser portion of the CU. The separation tank and water return system can be configured to separate the combustion exhaust constituents from the condensate. An evaporator portion of the CU can be fluidly coupled with the separation tank and water return system via an evaporator side condensate conduit.

Abstract: The present disclosure concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and R3 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cancer.

Abstract: A leak catching apparatus is provided. The leak catching apparatus may include a receiving device configured to receive a fluid leaking from a sealed system that contains liquid; an absorbent material positioned on the receiving device; and one or more attachment means coupled to the receiving device, wherein the one or more attachment means are configured to temporarily secure the receiving device to the sealed system, one or more structures associated with the sealed system, or a combination thereof.

Abstract: A system comprising a plasma assisted vitrifier (8) configured to produce vitrified product. A feed pipe (4) can be fluidly connected to the plasma assisted vitrifier (8). The feed pipe (4) can be configured to deliver a feedstock into the plasma assisted vitrifier. A heated combustion air conduit (34) can be fluidly connected to the plasma assisted vitrifier (8). A spinning fiberizer can be disposed next to the plasma assisted vitrifier (8) and configured to receive the vitrified product (24). An emissions attenuation device can be fluidly connected to the plasma-assisted vitrifier (8) and configured to treat gaseous emissions generated by the plasma-assisted vitrifier (8).

Abstract: A leak catching apparatus is provided. The leak catching apparatus may include a plate having a first section, a center section, and a second section, wherein the first section is non-coplanar with the second section; an absorbent material housed on the first section; one or more absorbent material attachments coupled to the first section to secure the absorbent material to the first section; and one or more plate attachments coupled to the first section and the second section, wherein the one or more plate attachments temporarily secures the first section and the second section to a sealed system that contains liquid.

Abstract: The present disclosure concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and R3 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cancer.

Abstract: A leak catching apparatus is provided. The leak catching apparatus may include a plate having a first section, a center section, and a second section, wherein the first section is non-coplanar with the second section; an absorbent material housed on the first section; one or more absorbent material attachments coupled to the first section to secure the absorbent material to the first section; and one or more plate attachments coupled to the first section and the second section, wherein the one or more plate attachments temporarily secures the first section and the second section to a sealed system that contains liquid.

Abstract: The present disclosure concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and R3 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cancer.

Abstract: The present invention relates to compounds that inhibit of focal adhesion kinase function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases such as cancer.

Abstract: The present invention relates to compounds that inhibit of focal adhesion kinase function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases such as cancer.

Abstract: The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R1, R2, R3, n and m are as described in the specification, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to a novel group of compounds of Formula (I) and to methods for preparing compounds of Formula (I).

Abstract: This invention relates to chemical compounds of the formula (I), or a pharmaceutically acceptable salt thereof, which possess inhibitory activity against the spindle checkpoint kinase: Tyrosine Threonine Kinase (TTK)/monopolar spindle 1 (Mps1) and are accordingly useful for their anti-cancer effect in a warm-blooded animal such as man. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them, and to their use in the manufacture of a medicament for the treatment of conditions mediated by TTK/Mps1, for use either alone or in combination with other anti-pro liferative agents.